Vimarsana
Biggest News Aggregation in the World

Page 11 - Gary Jacobs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gary Jacobs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gary Jacobs Today - Breaking & Trending Today

CHARGE ENTERPRISES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Vimarsana News

CHARGE ENTERPRISES, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 10, 2022, our Board of... | January 14, 2022

Charge Enterprises : Adds Three Independent Members to its Board of Directors - Form 8-K - Vimarsana News

Charge Enterprises : Adds Three Independent Members to its Board of Directors - Form 8-K

Charge Enterprises Adds Three Independent Members to its Board of Directors New York - Charge Enterprises, Inc. , consisting of a portfolio of global... | January 14, 2022

OKYO Pharma Limited's lead asset receives US patent protection covering its use in dry eye disease - Vimarsana News

OKYO Pharma Limited's lead asset receives US patent protection covering its use in dry eye disease

OK-101 is expected to go straight into phase II clinical trials in the fourth quarter of next year

OKYO Pharma Limited's lead asset receives US patent protection covering its use in dry eye disease - Vimarsana News

OKYO Pharma Limited's lead asset receives US patent protection covering its use in dry eye disease

OK-101 is expected to go straight into phase II clinical trials in the fourth quarter of next year

OKYO Pharma Ltd is looking to take its dry eye disease treatment straight into phase II clinical trials - Vimarsana News

OKYO Pharma Ltd is looking to take its dry eye disease treatment straight into phase II clinical trials

If all goes to plan, the study should begin in the fourth quarter of next year